Diabetes and chronic heart failure: From diabetic cardiomyopathy to therapeutic approach

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 13, Issue 1, 2013, Pages 38-50

  Dei Cas, A ^a   Spigoni, V ^b   Ridolfi, V ^a   Metra, M ^b  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Chronic heart failure; Diabetes mellitus; Diabetic cardiomyopathy; Molecular mechanisms; Structural alteration; Therapy

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADVANCED GLYCATION END PRODUCT; DIACYLGLYCEROL; FATTY ACID; GLIBENCLAMIDE; GLICLAZIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; METFORMIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; SITAGLIPTIN; SULFONYLUREA; TOLBUTAMIDE; TRIACYLGLYCEROL;

CALCIUM HOMEOSTASIS; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EPIGENETICS; HEART FAILURE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

CHRONIC DISEASE; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHIES; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN;

EID: 84875869766     PISSN: 18715303     EISSN: 22123873     Source Type: Journal    
DOI: 10.2174/1871530311313010006     Document Type: Review

References (151)

1. Bui, A.L.; Horwich, T.B. and Fonarow, G.C. (2011) Epidemiology and risk profile of heart failure. Nat. Rev. Cardiol., 8(1), 30-41.
2. Roger, V.L.; Go, A.S.; Lloyd-Jones, D.M.; Benjamin, E.J.; Berry, J.D.; Borden, W.B.; Bravata, D.M.; Dai, S.; Ford, E.S.; Fox, C.S.; Fullerton, H.J.; Gillespie, C.; Hailpern, S.M.; Heit, J.A.; Howard, V.J.; Kissela, B.M.; Kittner, S.J.; Lackland, D.T.; Lichtman, J.H.; Lisabeth, L.D.; Makuc, D.M.; Marcus, G.M.; Marelli, A.; Matchar, D.B.; Moy, C.S.; Mozaffarian, D.; Mussolino, M.E., Nichol, G.; Paynter, N.P.; Soliman, E.Z.; Sorlie, P.D.; Sotoodehnia, N.; Turan, T.N.; Virani, S.S.; Wong, N.D.; Woo, D.; Turner, M.B. (2012) Executive summary: heart disease and stroke statistics--2012 update: a report from the American Heart Association.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation, 125(1), 188-197.
3. Hall, M.J.; DeFrances, C.J.; Williams, S.N.; Golosinskiy, A. and Schwartzman, A. (2010) National Hospital Discharge Survey: 2007 summary. Natl. Health. Stat. Report., (29), 1-20, 24.
4. Lloyd-Jones, D.; Adams, R.; Carnethon, M.; De Simone, G.; Ferguson, T.B.; Flegal, K.; Ford, E.; Furie, K.; Go, A.; Greenlund, K.; Haase, N.; Hailpern, S.; Ho, M.; Howard, V.; Kissela, B.; Kittner, S.; Lackland, D.; Lisabeth, L.; Marelli, A.; McDermott, M.; Meigs, J.; Mozaffarian, D.; Nichol, G.; O'Donnell, C.; Roger, V.; Rosamond, W.; Sacco, R.; Sorlie, P.; Stafford, R.; Steinberger, J.; Thom, T.; Wasserthiel-Smoller, S.; Wong, N.; Wylie-Rosett, J.; Hong, Y. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. (2009) Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation, 119(3), 480-486.
5. McMurray, J.J.; Adamopoulos, S.; Anker, S.D.; Auricchio, A.; Böhm, M.; Dickstein, K.; Falk, V.; Filippatos, G.; Fonseca, C., Gomez-Sanchez, M.A.; Jaarsma, T.; Køber, L.; Lip, G.Y.; Maggioni, A.P.; Parkhomenko, A.; Pieske, B.M.; Popescu, B.A.; Rønnevik, P.K.; Rutten, F.H.; Schwitter, J.; Seferovic, P.; Stepinska, J.; Trindade, P.T.; Voors, A.A.; Zannad, F.; Zeiher, A. and ESC Committee for Practice Guidelines. (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. Heart J., 33(14), 1787-1847.
6. Bhatia, R.S.; Tu, J.V.; Lee, D.S.; Austin, P.C.; Fang, J.; Haouzi, A.; Gong, Y. and Liu, P.P. (2006) Outcome of heart failure with preserved ejection fraction in a population-based study. N. Engl. J. Med., 355(3), 260-269.
7. Aurigemma, G.P. (2006) Diastolic heart failure--a common and lethal condition by any name. N. Engl. J. Med., 355(3), 308-310.
8. King, H.; Aubert, R.E. and Herman, W.H. (1998) Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care, 21(9), 1414-1431.
9. Wild, S.; Roglic, G.; Green, A.; Sicree, R. and King, H. (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care, 27(5), 1047-1053.
10. Thrainsdottir, I.S.; Aspelund, T.; Thorgeirsson, G.; Gudnason, V.; Hardarson, T.; Malmberg, K.; Sigurdsson, G. and Rydén, L. (2005) The association between glucose abnormalities and heart failure in the population-based Reykjavik study. Diabetes Care, 28(3), 612-616.
11. Gottdiener, J.S.; Arnold, A.M.; Aurigemma, G.P.; Polak, J.F.; Tracy, R.P.; Kitzman, D.W.; Gardin, J.M.; Rutledge, J.E. and Boineau, R.C. (2000) Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J. Am. Coll. Cardiol., 35(6), 1628-1637.
12. Kannel, W.B. and McGee, D.L. (1979) Diabetes and cardiovascular disease. The Framingham study. JAMA, 241(19), 2035-2038.
13. The CONSENSUS trial study group (1987) Effect of enalapril on mortality in severe congestive heart failure. N. Engl. J. Med., 316, 1429-1435.
14. A.M.; Leibson, C.L.; Bursi, F.; Redfield, M.M.; Weston, S.A.; Jacobsen, S.J.; Rodeheffer, R.J. and Roger, V.L. (2006) Diabetes in heart failure: prevalence and impact on outcome in the population. Am. J. Med., 119(7), 591-599.
15. Iribarren, C.; Karter, A.J.; Go, A.S.; Ferrara, A.; Liu, J.Y.; Sidney, S. and Selby, J.V. (2001) Glycemic control and heart failure among adult patients with diabetes. Circulation, 103(22), 2668-2673.
16. MacDonald, M.R.; Petrie, M.C.; Varyani, F.; Ostergren, J.; Michelson, E.L.; Young, J.B.; Solomon, S.D.; Granger, C.B.; Swedberg, K.; Yusuf, S.; Pfeffer, M.A.; McMurray, J.J. and CHARM Investigators. (2008) Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur. Heart J., 29(11), 1377-1385.
17. Lind, M.; Bounias, I.; Olsson, M.; Gudbjörnsdottir, S.; Svensson, A.M.; Rosengren, A. (2011) Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational study. Lancet, 378(9786), 140-146.
18. Amato, L.; Paolisso, G.; Cacciatore, F.; Ferrara, N.; Ferrara, P.; Canonico, S.; Varricchio, M. and Rengo, F. (1997) Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group. Diabetes Metab., 23(3), 213-218.
19. Swan, J.W.; Anker, S.D.; Walton, C.; Godsland, I.F.; Clark, A.L.; Leyva, F.; Stevenson, J.C. and Coats, A.J. (1997) Insulin resistance in chronic heart failure: Relation to severity and etiology of heart failure. J. Am. Coll. Cardiol., 30, 527-532.
20. King, H.; Aubert, R.E. and Herman, W.H. (1998) Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care, 21(9), 1414-1431.
21. Danaei, G.; Finucane, M.M.; Lu, Y.; Singh, G.M.; Cowan, M.J.; Paciorek, C.J.; Lin, J.K.; Farzadfar, F.; Khang, Y.H.; Stevens, G.A.; Rao, M.; Ali, M.K.; Riley, L.M.; Robinson, C.A.; Ezzati, M. and Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose). (2011) National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet, 378(9785), 31-40.
22. Haffner, S.M.; Lehto, S.; Rönnemaa, T.; Pyörälä, K. and Laakso, M. (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med., 339(4), 229-234.
23. Stamler, J.; Vaccaro, O.; Neaton, J.D. and Wentworth, D. (1993) Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care, 16(2), 434-444.
24. van Melle, J.P.; Bot, M.; de Jonge, P.; de Boer, R.A.; van Veldhuisen, D.J. and Whooley, M.A. (2010) Diabetes, glycemic control, and new-onset heart failure in patients with stable coronary artery disease: data from the heart and soul study. Diabetes Care, 33(9), 2084-2089.
25. Rubler, S.; Dlugash, J.; Yuceoglu, Y.Z.; Kumral, T.; Branwood, A.W. and Grishman, A. (1972) New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am. J. Cardiol., 30(6), 595-602.
26. Hayat, S.A.; Patel, B.; Khattar, R.S. and Malik, R.A. (2004) Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. Clin. Sci., 107(6), 539-557.
27. Schannwell, C.M.; Schneppenheim, M.; Perings, S.; Plehn, G. and Strauer, B.E. (2002) Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathy. Cardiology, 98(1-2), 33-39.
28. UK Prospective Diabetes Study Group (1995) UK prospective diabetes study 16: overview of 6 years of therapy of type II diabetes: a progressive disease. Diabetes, 44, 1249-1258.
29. Boudina, S. and Abel, E.D. (2007) Diabetic cardiomyopathy revisited. Circulation, 115(25), 3213-3223.
30. Lopaschuk, G.D. (2002) Metabolic abnormalities in the diabetic heart. Heart Fail. Rev., 7(2), 149-159.
31. Carroll, R.; Carley, A.N.; Dyck, J.R. and Severson, D.L. (2005) Metabolic effects of insulin on cardiomyocytes from control and diabetic db/db mouse hearts. Am. J. Physiol. Endocrinol. Metab., 288(5), E900-906.
32. Herrero, P.; Peterson, L.R.; McGill, J.B.; Matthew, S.; Lesniak, D.; Dence, C. and Gropler, R.J. (2006) Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. J. Am. Coll. Cardiol., 47(3), 598-604.
33. Heather, L.C. and Clarke, K. (2011) Metabolism, hypoxia and the diabetic heart. J. Mol. Cell. Cardiol., 50(4), 598-605.
34. Buchanan, J.; Mazumder, P.K.; Hu, P.; Chakrabarti, G.; Roberts, M.W.; Yun, U.J.; Cooksey, R.C.; Litwin, S.E. and Abel, E.D. (2005) Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology, 146(12), 5341-5349.
35. Sharma, S.; Adrogue, J.V.; Golfman, L.; Uray, I.; Lemm, J.; Youker, K.; Noon, G.P.; Frazier, O.H. and Taegtmeyer, H. (2004) Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J. 18(14), 1692-1700.
36. Finck, B.N.; Lehman, J.J.; Leone, T.C.; Welch, M.J.; Bennett, M.J.; Kovacs, A.; Han, X.; Gross, R.W.; Kozak, R.; Lopaschuk, G.D. and Kelly, D.P. (2002) The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J. Clin. Invest., 109(1), 121-130.
37. Mazumder, P.K.; O'Neill, B.T.; Roberts, M.W.; Buchanan, J.; Yun, U.J.; Cooksey, R.C.; Boudina, S. and Abel, E.D. (2004) Impaired cardiac efficiency and increased fatty acid oxidation in insulinresistant ob/ob mouse hearts. Diabetes, 53(9), 2366-2374.
38. How, O.J.; Aasum, E.; Severson, D.L.; Chan, W.Y.; Essop, M.F. and Larsen, T.S. (2006) Increased myocardial oxygen consumption reduces cardiac efficiency in diabetic mice. Diabetes, 55(2), 466-473.
39. Mazumder, P.K.; O'Neill, B.T.; Roberts, M.W.; Buchanan, J.; Yun, U.J.; Cooksey, R.C.; Boudina, S. and Abel, E.D. (2004) Impaired cardiac efficiency and increased fatty acid oxidation in insulinresistant ob/ob mouse hearts. Diabetes, 53(9), 2366-2374.
40. Szczepaniak, L.S.; Dobbins, R.L.; Metzger, G.J.; Sartoni-D'Ambrosia, G.; Arbique, D.; Vongpatanasin, W.; Unger, R. and Victor, R.G. (2003) Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn. Reson. Med., 49(3), 417-423.
41. Després, J.P. and Lemieux, I. (2006) Abdominal obesity and metabolic syndrome. Nature, 444(7121), 881-887.
42. Lewis, G.F.; Carpentier, A.; Adeli, K. and Giacca, A. (2002) Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr. Rev., 23(2), 201-229.
43. Wang, C.N.; O'Brien, L. and Brindley, D.N. (1998) Effects of cellpermeable ceramides and tumor necrosis factor-alpha on insulin signaling and glucose uptake in 3T3-L1 adipocytes. Diabetes, 47(1), 24-31.
44. Dey, D.; Basu, D.; Roy, S.S.; Bandyopadhyay, A. and Bhattacharya, S. (2006) Involvement of novel PKC isoforms in FFA induced defects in insulin signaling. Mol. Cell. Endocrinol., 246(1-2), 60-64.
45. Retnakaran, R. and Zinman, B. (2008) Type 1 diabetes, hyperglycaemia, and the heart. Lancet, 371(9626), 1790-1799.
46. Ginsberg, B.J. and Mazze, R. (1994) Clinical consequences of the Diabetes Control and Complications Trial. N. J. Med., 91(4), 221-224.
47. Wang, J.; Song, Y.; Wang, Q.; Kralik, P.M. and Epstein, P.N. (2006) Causes and characteristics of diabetic cardiomyopathy. Rev. Diabet. Stud., 3(3), 108-117.
48. Hartog, J.W.; Voors, A.A.; Bakker, S.J.; Smit, A.J. and van Veldhuisen, D.J. (2007) Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. Eur. J. Heart Fail., 9(12), 1146-1155.
49. Mizushige, K.; Yao, L.; Noma, T.; Kiyomoto, H.; Yu, Y.; Hosomi, N.; Ohmori, K. and Matsuo, H. (2000) Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulinresistant prediabetic stage of a type II diabetic rat model. Circulation, 101(8), 899-907.
50. Bierhaus, A.; Hofmann, M.A.; Ziegler, R. and Nawroth, P.P. (1998) The AGE/RAGE pathway in vascular disease and diabetes mellitus. Part I. The AGE-concept. Cardiovasc. Res., 37, 586-600.
51. Striker, G.E.; Eastman, R.D.; Striker, L.J. (1996) Diabetic nephropathy: molecular analysis of extracellular matrix and clinical studies update. Nephrol. Dial. Transplant., 5, 58-61.
52. Bierhaus, A.; Chevion, S.; Chevion, M.; Hofmann, M.; Quehenberger, P.; Illmer, T.; Luther, T.; Berentshtein, E.; Tritschler, H.; Müller, M.; Wahl, P.; Ziegler, R. and Nawroth, P.P. (1997) Advanced glycation end product-induced activation of NFkappaB is suppressed by alpha-lipoic acid in cultured endothelial cells. Diabetes, 46(9), 1481-1490.
53. Bierhaus, A.; Schiekofer, S.; Schwaninger, M.; Andrassy, M.; Humpert, P.M.; Chen, J.; Hong, M.; Luther, T.; Henle, T.; Klöting, I.; Morcos, M.; Hofmann, M.; Tritschler, H.; Weigle, B.; Kasper, M.; Smith, M.; Perry, G.; Schmidt, A.M.; Stern, D.M.; Häring, H.U.; Schleicher, E. and Nawroth, P.P. (2001) Diabetes-associated sustained activation of the transcription factor nuclear factorkappaB. Diabetes, 50(12), 2792-2808.
54. Petrova, R.; Yamamoto, Y.; Muraki, K.; Yonekura, H.; Sakurai, S.; Watanabe, T.; Li, H.; Takeuchi, M.; Makita, Z.; Kato, I.; Takasawa, S.; Okamoto, H.; Imaizumi, Y. and Yamamoto, H. (2002) Advanced glycation endproduct-induced calcium handling impairment in mouse cardiac myocytes. J. Mol. Cell. Cardiol., 34(10), 1425-1431.
55. van Heerebeek, L.; Hamdani, N.; Handoko, M.L.; Falcao-Pires, I.; Musters, R.J.; Kupreishvili, K.; Ijsselmuiden, A.J.; Schalkwijk, C.G.; Bronzwaer, J.G.; Diamant, M.; Borbély, A.; van der Velden, J.; Stienen, G.J.; Laarman, G.J.; Niessen, H.W. and Paulus, W.J. (2008) Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation, 117(1), 43-51.
56. Koyama, Y.; Takeishi, Y.; Niizeki, T.; Suzuki, S.; Kitahara, T.; Sasaki, T. and Kubota, I. (2008) Soluble Receptor for advanced glycation end products (RAGE) is a prognostic factor for heart failure. J. Card. Fail., 14(2), 133-139.
57. Geraldes, P. and King, G.L. (2010) Activation of protein kinase C isoforms and its impact on diabetic complications.). Circ. Res., 106(8), 1319-1331.
58. Sheetz, M.J.; King, G.L. (2002) Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA, 288(20), 2579-2588.
59. Ceolotto, G.; Gallo, A.; Miola, M.; Sartori, M.; Trevisan, R.; Del Prato, S.; Semplicini, A. and Avogaro, A. (1999) Protein kinase C activity is acutely regulated by plasma glucose concentration in human monocytes in vivo. Diabetes, 48(6), 1316-1322.
60. Way, K.J.; Isshiki, K.; Suzuma, K.; Yokota, T.; Zvagelsky, D.; Schoen, F.J.; Sandusky, G.E.; Pechous, P.A.; Vlahos, C.J.; Wakasaki, H. and King, G.L. (2002) Expression of connective tissue growth factor is increased in injured myocardium associated with protein kinase C beta2 activation and diabetes. Diabetes, 51(9), 2709-2718.
61. Wakasaki, H.; Koya, D.; Schoen, F.J.; Jirousek, M.R.; Ways, D.K.; Hoit, B.D.; Walsh, R.A. and King, G.L. (1997) Targeted overexpression of protein kinase C 2 isoform in myocardium causes cardiomyopathy. Proc. Natl. Acad. Sci. USA, 94, 9320-9325.
62. Connelly, K.A.; Kelly, D.J.; Zhang, Y.; Prior, D.L.; Advani, A.; Cox, A.J.; Thai, K.; Krum, H. and Gilbert, R.E. (2009) Inhibition of protein kinase C-beta by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy. Circ. Heart Fail., 2(2), 129-137.
63. Yang, Z.; Zingarelli, B. and Szabo, C. (2000) Effect of genetic disruption of poly (ADP-ribose) synthetase on delayed production of inflammatory mediators and delayed necrosis during myocardial ischemia-reperfusion injury. Shock, 13(1), 60-66.
64. Szabó, C. (2005) Roles of poly(ADP-ribose) polymerase activation in the pathogenesis of diabetes mellitus and its complications. Pharmacol. Res., 52(1), 60-71.
65. Minchenko, A.G.; Stevens, M.J.; White, L.; Abatan, O.I.; Komjáti, K.; Pacher, P.; Szabó, C. and Obrosova, I.G. (2003) Diabetesinduced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose) polymerase activation. FASEB Journal, 17(11), 1514-1516.
66. Wold, L.E. and Ren, J. (2004) Streptozotocin directly impairs cardiac contractile function in isolated ventricular myocytes via a p38 map kinase dependent oxidative stress mechanism. Biochem. Biophys. Res. Commun., 318, 1066-1107.
67. Boudina, S.; Sena, S.; O'Neill, B.T.; Tathireddy, P.; Young, M.E. and Abel, E.D. (2005) Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity. Circulation, 112(17), 2686-2695.
68. Steinberg, H.O.; Paradisi, G.; Hook, G.; Crowder, K.; Cronin, J. and Baron, A.D. (2000) Free fatty acid elevation impairs insulinmediated vasodilation and nitric oxide production. Diabetes, 49(7), 1231-1238.
69. Imrie, H.; Abbas, A. and Kearney, M. (2010) Insulin resistance, lipotoxicity and endothelial dysfunction. Biochim. Biophys. Acta., 1801(3), 320-326.
70. rd; Gunasinghe, H.R.; Mukherjee, R.; Zile, M.R.; O'Neill, T.P. and Spinale, F.G. (2003) Selective matrix metalloproteinase inhibition with developing heart failure: effects on left ventricular function and structure. Circ. Res., 92, 177-185.
71. Cesselli, D.; Jakoniuk, I.; Barlucchi, L.; Beltrami, A.P.; Hintze, T.H.; Nadal-Ginard, B.; Kajstura, J.; Leri, A. and Anversa, P. (2001) Oxidative stress-mediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy. Circ. Res., 89, 279-286.
72. Takano, H.; Zou, Y.; Hasegawa, H.; Akazawa, H.; Nagai, T. and Komuro, I. (2003) Oxidative stress-induced signal transduction pathways in cardiac myocytes: involvement of ROS in heart diseases. Antioxid. Redox Signal, 5, 789-794.
73. Malhotra, A. and Sanghi, V. (1997) Regulation of contractile proteins in diabetic heart. Cardiovas. Res., 34(1), 34-40.
74. Teshima, Y.; Takahashi, N.; Saikawa, T.; Hara, M.; Yasunaga, S.; Hidaka, S. and Sakata, T. (2000) Diminished expression of sarcoplasmic reticulum Ca(2+)-ATPase and ryanodine sensitive Ca(2+)Channel mRNA in streptozotocin-induced diabetic rat heart. J. Mol. Cell. Cardiol., 32(4), 655-664.
75. Xu, J.; Zhou, Q.; Xu, W. and Cai, L. (2012) Endoplasmic reticulum stress and diabetic cardiomyopathy. Exp. Diabetes Res., 2012, 827-971.
76. Hattori, Y.; Matsuda, N.; Kimura, J.; Ishitani, T.; Tamada, A.; Gando, S.; Kemmotsu, O. and Kanno, M. (2000) Diminished function and expression of the cardiac Na+-Ca2+ exchanger in diabetic rats: implication in Ca2+ overload. J. Physiol., 527(Pt 1), 85-94.
77. Choi, K.M.; Zhong, Y.; Hoit, B.D.; Grupp, I.L.; Hahn, H.; Dilly, K.W.; Guatimosim, S.; Lederer, W.J. and Matlib, M.A. (2002) Defective intracellular Ca(2+) signaling contributes to cardiomyopathy in Type 1 diabetic rats. Am. J. Physiol. Heart Circ. Physiol., 283(4), H1398-1408.
78. Tang, W.H.; Cheng, W.T.; Kravtsov, G.M.; Tong, X.Y.; Hou, X.Y.; Chung, S.K. and Chung, S.S. (2010) Cardiac contractile dysfunction during acute hyperglycemia due to impairment of SERCA by polyol pathway-mediated oxidative stress. Am. J. Physiol. Cell. Physiol., 299(3), C643-C653.
79. Trost, S.U.; Belke, D.D.; Bluhm, W.F.; Meyer, M.; Swanson, E. and Dillmann, W.H. (2002) Overexpression of the sarcoplasmic reticulum Ca(2+)-ATPase improves myocardial contractility in diabetic cardiomyopathy. Diabetes, 51(4), 1166-1171.
80. Razeghi, P.; Young, M.E.; Cockrill, T.C.; Frazier, O.H. and Taegtmeyer, H. (2002) Downregulation of myocardial myocyte enhancer factor 2C and myocyte enhancer factor 2C-regulated gene expression in diabetic patients with nonischemic heart failure. Circulation, 106(4), 407-411.
81. Jweied, E.E.; McKinney, R.D.; Walker, L.A.; Brodsky, I.; Geha, A.S.; Massad, M.G.; Buttrick, P.M. and de Tombe, P.P. (2005) Depressed cardiac myofilament function in human diabetes mellitus. Am. J. Physiol. Heart Circ. Physiol., 289(6), H2478-2483.
82. Zhang, L.; Cannell, M.B.; Phillips, A.R.; Cooper, G.J. and Ward, M.L. (2008) Altered calcium homeostasis does not explain the contractile deficit of diabetic cardiomyopathy. Diabetes, 57(8), 2158-2166.
83. Lim, H.S.; MacFadyen, R.J. and Lip, G.Y. (2004) Diabetes mellitus, the renin-angiotensin-aldosterone system, and the heart. Arch. Intern. Med., 164(16), 1737-1748.
84. Pratt, R.E. (1999) Angiotensin II and the control of cardiovascular structure. J. Am. Soc. Nephrol., 10, S120-128.
85. Frustaci, A.; Kajstura, J.; Chimenti, C.; Jakoniuk, I.; Leri, A.; Maseri, A.; Nadal-Ginard, B. and Anversa, P. (2000) Myocardial cell death in human diabetes. Circ. Res., 87(12), 1123-1132.
86. He, Z.; Way, K.J.; Arikawa, E.; Chou, E.; Opland, D.M.; Clermont, A.; Isshiki, K.; Ma, R.C.; Scott, J.A.; Schoen, F.J.; Feener, E.P. and King, G.L. (2005) Differential regulation of angiotensin II-induced expression of connective tissue growth factor by protein kinase C isoforms in the myocardium. J. Biol. Chem., 280(16), 15719-15726.
87. Fiordaliso, F.; Cuccovillo, I.; Bianchi, R.; Bai, A.; Doni, M.; Salio, M.; De Angelis, N.; Ghezzi, P.; Latini, R. and Masson, S. (2006) Cardiovascular oxidative stress is reduced by an ACE inhibitor in a rat model of streptozotocin-induced diabetes. Life Sci., 79(2), 121-129.
88. Liu, X.; Suzuki, H.; Sethi, R.; Tappia, P.S.; Takeda, N. and Dhalla, N.S. (2006) Blockade of the renin-angiotensin system attenuates sarcolemma and sarcoplasmic reticulum remodeling in chronic diabetes. Ann. N. Y. Acad. Sci., 1084, 141-154.
89. Yaras, N.; Bilginoglu, A.; Vassort, G. and Turan, B. (2007) Restoration of diabetes-induced abnormal local Ca2+ release in cardiomyocytes by angiotensin II receptor blockade. Am. J. Physiol. Heart Circ. Physiol., 292(2), H912-920.
90. Shen, X.; Zheng, S.; Thongboonkerd, V.; Xu, M.; Pierce, W.M. Jr; Klein, J.B. and Epstein, P.N. (2004) Cardiac mitochondrial damage and biogenesis in a chronic model of type 1 diabetes. Am. J. Physiol. Endocrinol. Metab., 287(5), E896-905.
91. Ye, G.; Metreveli, N.S.; Donthi, R.V.; Xia, S.; Xu, M.; Carlson, E.C. and Epstein, P.N. (2004) Catalase protects cardiomyocyte function in models of type 1 and type 2 diabetes. Diabetes, 53(5), 1336-1343.
92. Shen, X.; Zheng, S.; Metreveli, N.S. and Epstein, P.N. (2006) Protection of cardiac mitochondria by overexpression of MnSOD reduces diabetic cardiomyopathy. Diabetes, 55(3), 798-800.
93. Boudina, S.; Bugger, H.; Sena, S.; O'Neill, B.T.; Zaha, V.G.; Ilkun, O.; Wright, J.J.; Mazumder, P.K.; Palfreyman, E.; Tidwell, T.J.; Theobald, H.; Khalimonchuk, O.; Wayment, B.; Sheng, X.; Rodnick, K.J.; Centini, R.; Chen, D.; Litwin, S.E.; Weimer, B.E. and Abel, E.D. (2009) Contribution of impaired myocardial insulin signaling to mitochondrial dysfunction and oxidative stress in the heart. Circulation, 119(9), 1272-1283.
94. Metzler, B.; Schocke, M.F.; Steinboeck, P.; Wolf, C.; Judmaier, W.; Lechleitner, M.; Lukas, P. and Pachinger, O. (2002) Decreased high-energy phosphate ratios in the myocardium of men with diabetes mellitus type I. J. Cardiovasc. Magn. Reson., 4(4), 493-502.
95. Anderson, E.J.; Kypson, A.P.; Rodriguez, E.; Anderson, C.A.; Lehr, E.J. and Neufer, P.D. (2009) Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart. J. Am. Coll. Cardiol., 54(20), 1891-1898.
96. Singh, G.B.; Sharma, R. and Khullar, M. (2011) Epigenetics and diabetic cardiomyopathy. Diabetes Res. Clin. Pract., 94(1), 14-21.
97. Villeneuve, L.M. and Natarajan, R. (2010) The role of epigenetics in the pathology of diabetic complications. Am. J. Physiol. Renal. Physiol., 299(1), F14-25.
98. Fang, Z.Y.; Prins, J.B. and Marwick, T.H. (2004) Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr. Rev., 25(4), 543-567.
99. Kawaguchi, M.; Techigawara, M.; Ishihata, T.; Asakura, T.; Saito, F.; Maehara, K. and Maruyama, Y. (1997) A comparison of ultrastructural changes on endomyocardial biopsy specimens obtained from patients with diabetes mellitus with and without hypertension. Heart Vessels, 12(6), 267-274.
100. Rubler, S.; Dlugash, J.; Yuceoglu, Y.Z.; Kumral, T.; Branwood, A.W. and Grishman, A. (1972) New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am. J. Cardiol., 30(6), 595-602.
101. van Hoeven, K.H. and Factor, S.M. (1990) A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensivediabetic heart disease. Circulation, 82(3), 848-855.
102. Gonzalez-Vilchez, F.; Ayuela, J.; Ares, M.; Pi, J.; Castillo, L. and Martin-Duran, R. (2005) Oxidative stress and fibrosis in incipient myocardial dysfunction in type 2 diabetic patients. Int. J. Cardiol., 101(1), 53-58.
103. Ihm, S.H.; Youn, H.J.; Shin, D.I.; Jang, S.W.; Park, C.S.; Kim, P.J.; Kim, H.Y.; Chang, K.; Seung, K.B.; Kim, J.H. and Choi, K.B. (2007) Serum carboxy-terminal propeptide of type I procollagen (PIP) is a marker of diastolic dysfunction in patients with early type 2 diabetes mellitus. Int. J. Cardiol., 122(3), e36-38.
104. Fischer, V.W.; Barner, H.B. and Larose, L.S. (1984) Pathomorphologic aspects of muscular tissue in diabetes mellitus. Hum. Pathol., 15(12), 1127-1136.
105. Miki, T.; Yuda, S.; Kouzu, H. and Miura, T. (2012) Diabetic cardiomyopathy: pathophysiology and clinical features. Heart. Fail. Rev., 18(2), 149-66.
106. Mytas, D.Z.; Stougiannos, P.N.; Zairis, M.N.; Foussas, S.G.; Pyrgakis, V.N. and Kyriazis, I.A. (2009) Diabetic myocardial disease: pathophysiology, early diagnosis and therapeutic options. J. Diab. Complications, 23(4), 273-282.
107. Voulgari, C.; Papadogiannis, D. and Tentolouris, N. (2010) Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies. Vasc. Health. Risk. Manag., 6, 883-903.
108. Voors, A.A.; van der Horst, I.C. (2011) Diabetes: a driver for heart failure. Heart, 97(9), 774-780.
109. Boyer, J.K.; Thanigaraj, S.; Schechtman, K.B. and Perez, J.E. (2004) Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am. J. Cardiol., 93(7), 870-875.
110. Fang, Z.Y.; Schull-Meade, R.; Leano, R.; Mottram, P.M.; Prins, J.B. and Marwick, T.H. (2005) Screening for heart disease in diabetic subjects. Am. Heart J., 149(2), 349-354.
111. Annonu, A.K.; Fattah, A.A.; Mokhtar, M.S.; Ghareeb, S. and Elhendy, A. (2001) Left ventricular systolic and diastolic functional abnormalities in asymptomatic patients with non-insulin-dependent diabetes mellitus. J. Am. Soc. Echocardiogr., 14(9), 885-891.
112. Gerstein, H.C.; Swedberg, K.; Carlsson, J.; McMurray, J.J.; Michelson, E.L.; Olofsson, B.; Pfeffer, M.A.; Yusuf, S. and CHARM Program Investigators (2008) The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Arch. Intern. Med., 168(15), 1699-1704.
113. Shindler, D.M.; Kostis, J.B.; Yusuf, S.; Quinones, M.A.; Pitt, B.; Stewart, D.; Pinkett, T.; Ghali, J.K. and Wilson, A.C. (1996) Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) trials and registry. Am. J. Cardiol., 77, 1017-1020.
114. Bourassa, M.G.; Gurné, O.; Bangdiwala, S.I.; Ghali, J.K.; Young, J.B.; Rousseau, M.; Johnstone, D.E. and Yusuf, S. (1993) Natural history and patterns of current practice in heart failure. The Studies of Left Ventricular Dysfunction (SOLVD) Investigators. J. Am. Coll. Cardiol., 22(4 Suppl A), 14A-19A.
115. The SOLVD Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med., 325, 293-302.
116. Nodari, S.; Manerba, A.; Vaccari, A.; Milesi, G.; Carubelli, V.; Lazzarini, V.; Lombardi, C.; Ettori, F.; Metra, M. and Dei Cas, A. (2012) Six-year prognosis of diabetic patients with coronary artery disease. Eur. J. Clin. Invest., 42(4), 376-383.
117. Deedwania, P.C.; Ahmed, M.I.; Feller, M.A., Aban, I.B.; Love, T.E.; Pitt, B. and Ahmed, A. (2011) Impact of diabetes mellitus on outcomes in patients with acute myocardial infarction and systolic heart failure. Eur. J. Heart Fail., 13(5), 551-559.
118. Baliga, V. and Sapsford, R. (2009) Review article: Diabetes mellitus and heart failure--an overview of epidemiology and management. Diab. Vasc. Dis. Res., 6(3), 164-171.
119. Hordern, M.D.; Coombes, J.S.; Cooney, L.M.; Jeffriess, L.; Prins, J.B. and Marwick, T.H. (2009) Effects of exercise intervention on myocardial function in type 2 diabetes. Heart, 95(16), 1343-1349.
120. von Bibra, H.; Hansen, A.; Dounis, V.; Bystedt, T.; Malmberg, K. and Rydén, L. (2004) Augmented metabolic control improves myocardial diastolic function and perfusion in patients with noninsulin dependent diabetes. Heart, 90(12), 1483-1484.
121. Gaede, P.; Vedel, P.; Larsen, N.; Jensen, G.V.; Parving, H.H. and Pedersen, O. (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med., 348(5), 383-393.
122. Inzucchi, S.E.; Bergenstal, R.M.; Buse, J.B.; Diamant, M.; Ferrannini, E.; Nauck, M.; Peters, A.L.; Tsapas, A.; Wender, R.; Matthews, D.R.; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD) (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 35(6), 1364-1379.
123. Masoudi, F.A.; Inzucchi, S.E.; Wang, Y.; Havranek, E.P.; Foody, J.M. and Krumholz, H.M. (2005) Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation, 111(5), 583-590.
124. Eurich, D.T.; Majumdar, S.R.; McAlister, F.A.; Tsuyuki, R.T. and Johnson, J.A. (2005) Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care, 28(10), 2345-2351.
125. Tahrani, A.A.; Varughese, G.I.; Scarpello, J.H. and Hanna, F.W. (2007) Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated? BMJ, 335(7618), 508-512.
126. Eurich, D.T.; McAlister, F.A.; Blackburn, D.F.; Majumdar, S.R.; Tsuyuki, R.T.; Varney, J. and Johnson, J.A. (2007) Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ, 335(7618), 497.
127. Shah, D.D.; Fonarow, G.C. and Horwich, T.B. (2010) Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes. J. Card. Fail., 16(3), 200-206.
128. Lago, R.M.; Singh, P.P. and Nesto, R.W. (2007) Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet, 370(9593), 1129-1136.
129. Horio, T.; Suzuki, M.; Suzuki, K.; Takamisawa, I.; Hiuge, A.; Kamide, K.; Takiuchi, S.; Iwashima, Y.; Kihara, S.; Funahashi, T.; Yoshimasa, Y. and Kawano, Y. (2005) Pioglitazone improves left ventricular diastolic function in patients with essential hypertension. Am. J. Hypertens., 18(7), 949-957.
130. Karter, A.J.; Ahmed, A.T.; Liu, J.; Moffet, H.H. and Parker, M.M. (2005) Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet. Med., 22(8), 986-993.
131. Erdmann, E.; Charbonnel, B.; Wilcox, R.G.; Skene, A.M.; Massi-Benedetti, M.; Yates, J.; Tan, M.; Spanheimer, R.; Standl, E.; Dormandy, J.A. and PROactive investigators. (2007) Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care, 30(11), 2773-2778.
132. Lefer, D.J.; Nichols, C.G. and Coetzee, W.A. (2009) Sulfonylurea receptor 1 subunits of ATP-sensitive potassium channels and myocardial ischemia/reperfusion injury. Trends. Cardiovasc. Med., 19(2), 61-67.
133. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 352(9131), 837-853.
134. Andersson, C.; Gislason, G.H.; Jørgensen, C.H.; Hansen, P.R.; Vaag, A.; Sørensen, R.; Mérie, C.; Olesen, J.B.; Weeke, P.; Schmiegelow, M.; Norgaard, M.L.; Køber, L. and Torp-Pedersen, C. (2011) Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure. Diabetes Res. Clin. Pract., 94(1), 119-125.
135. Tzoulaki, I.; Molokhia, M.; Curcin, V.; Little, M.P.; Millett, C.J.; Ng, A.; Hughes, R.I.; Khunti, K., Wilkins, M.R.; Majeed, A. and Elliott, P. (2009) Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ, 339, b4731.
136. McAlister, F.A.; Eurich, D.T.; Majumdar, S.R. and Johnson, J.A. (2008) The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy. Eur. J. Heart. Fail., 10(7), 703-708.
137. Maru, S.; Koch, G.G.; Stender, M.; Clark, D.; Gibowski, L.; Petri, H.; White, A.D. and Simpson, R.J. Jr. (2005) Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting. Diabetes Care, 28(1), 20-26.
138. Garratt, K.N.; Brady, P.A.; Hassinger, N.L.; Grill, D.E.; Terzic, A. and Holmes, D.R. Jr. (1999) Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J. Am. Coll. Cardiol., 33(1), 119-124.
139. Jørgensen, C.H.; Gislason, G.H.; Bretler, D.; Sørensen, R.; Norgaard, M.L.; Hansen, M.L.; Schramm, T.K.; Abildstrom, S.Z. Torp-Pedersen, C., Hansen, P.R. (2011) Glyburide increases risk in patients with diabetes mellitus after emergent percutaneous intervention for myocardial infarction--a nationwide study. Int. J. Cardiol., 152(3), 327-331.
140. Klepzig, H., Kober, G.; Matter, C.; Luus, H.; Schneider, H.; Boedeker, K.H.; Kiowski, W.; Amann, F.W.; Gruber, D.; Harris, S.; Burger, W. (1999) Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur. Heart J., 20(6), 439-446.
141. Smooke, S.; Horwich, T.B. and Fonarow, G.C. (2005) Insulintreated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am. Heart J., 149(1), 168-174.
142. Eshaghian, S.; Horwich, T.B. and Fonarow, G.C. (2006) An unexpected inverse relationship between HbA1c levels and mortality in patients with diabetes and advanced systolic heart failure. Am. Heart J., 151(1), 91.
143. Toft-Nielsen, M.B.; Damholt, M.B.; Madsbad, S.; Hilsted, L.M.; Hughes, T.E., Michelsen, B.K. and Holst, J.J. (2001) Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J. Clin. Endocrinol. Metab., 86(8), 3717-3723.
144. Liu, Q.; Anderson, C.; Broyde, A., Polizzi, C.; Fernandez, R.; Baron, A. and Parkes, D.G. (2010) Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovasc. Diabetol., 9, 76.
145. Poornima, I.; Brown, S.B.; Bhashyam, S.; Parikh, P.; Bolukoglu, H. and Shannon, R.P. (2008) Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circ. Heart Fail., 1(3), 153-160.
146. Vyas, A.K.; Yang, K.C.; Woo, D.; Tzekov, A.; Kovacs, A.; Jay, P.Y. and Hruz, P.W. (2011) Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy. PLoS One, 6(2), e17178.
147. Khan, M.A.; Deaton, C.; Rutter, M.K.; Neyses, L. and Mamas, M.A. (2012) Incretins as a novel therapeutic strategy in patients with diabetes and heart failure. Heart Fail. Rev., 18(2), 141-148.
148. Best, J.H.; Maggs, D.; Little, W.; Chiquette, E. and Saunders, W.B. (2011) The risk of heart failure among patients receiving exenatide twice daily versus other glucose-lowering medications for diabetes: a matched retrospective analysis of the GE Healthcare EMR data. Diabetologia, 54(Suppl. 1), S1-S542.
149. Best, J.H.; Hoogwerf, B.J.; Herman, W.H.; Pelletier, E.M.; Smith, D.B.; Wenten, M. and Hussein, M.A. (2011) Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care, 34(1), 90-95.
150. Ratner, R.; Han, J.; Nicewarner, D.; Yushmanova, I.; Hoogwerf, B.J. and Shen, L. (2011) Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc. Diabetol., 10, 22.
151. Read, P.A., Khan, F.Z.; Heck, P.M.; Hoole, S.P. and Dutka, D.P. (2010) DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ. Cardiovasc. Imaging, 3(2), 195-201.